Sleep Cycle Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Sleep Cycle de 13.3% y 10% por año respectivamente. Se prevé que el BPA disminuya en un 19.7% al año. Se espera que la rentabilidad financiera sea de 28.2% en 3 años.
Información clave
13.3%
Tasa de crecimiento de los beneficios
-19.71%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Software | 35.2% |
| Tasa de crecimiento de los ingresos | 10.0% |
| Rentabilidad financiera futura | 28.17% |
| Cobertura de analistas | Low |
| Última actualización | 30 Apr 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00
It's been a sad week for Sleep Cycle AB (publ) ( STO:SLEEP ), who've watched their investment drop 17% to kr15.34 in...Artículo de análisis • Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
As you might know, Sleep Cycle AB (publ) ( STO:SLEEP ) last week released its latest first-quarter, and things did not...Recent updates
Artículo de análisis • May 02
Earnings Release: Here's Why Analysts Cut Their Sleep Cycle AB (publ) (STO:SLEEP) Price Target To kr29.00
It's been a sad week for Sleep Cycle AB (publ) ( STO:SLEEP ), who've watched their investment drop 17% to kr15.34 in...
Actualización del análisis • Apr 21
SLEEP: Respiratory Research And Apnea Launch Will Support 2027 Margin Recovery
Analysts keep their SEK35.0 price target for Sleep Cycle unchanged, citing offsetting shifts in key model inputs such as slightly lower revenue growth assumptions, a reduced profit margin outlook, a marginally lower discount rate and a higher future P/E multiple. What's in the News Sleep Cycle renewed its partnership with Revolut through June 2027, keeping its premium features bundled into Revolut’s Premium, Metal and Ultra tiers and extending reach to Revolut’s global user base (Client Announcements).
Actualización del análisis • Apr 04
SLEEP: Respiratory Disease Research Collaboration Will Drive Long Term Upside Potential
Analysts now see Sleep Cycle's fair value at SEK 30.75, down from SEK 39.50, reflecting updated views on revenue growth, profit margins and an outlook that applies a higher discount rate along with a much higher future P/E assumption. What's in the News Sleep Cycle introduced an AI-powered Sleep Score that focuses on duration, quality and routine.Actualización del análisis • Mar 21
SLEEP: Respiratory Research Collaborations Will Support 2027 Margin Recovery Upside
Analysts have maintained their SEK 35.00 price target on Sleep Cycle, with only small tweaks to assumptions around discount rate, revenue, profit margin and future P/E, reflecting a broadly steady outlook on the shares. What's in the News Sleep Cycle began a five-year research collaboration with The Delphi Group at Carnegie Mellon University, providing deidentified sleep-based cough and breathing data to support research on respiratory disease surveillance and early detection of seasonal and emerging outbreaks, including influenza, RSV and SARS-CoV-2.Actualización del análisis • Mar 06
SLEEP: Research Partnerships And 2027 Margin Recovery Will Drive Long Term Upside
Analysts are keeping their SEK price target for Sleep Cycle unchanged. A fair value of SEK 35.00 is maintained, as small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions effectively offset one another.Actualización del análisis • Feb 19
SLEEP: Licensing Deals And 2027 Margin Recovery Will Drive Long Term Upside
Analysts have reduced their Sleep Cycle fair value estimate from SEK 43.0 to SEK 35.0, reflecting a higher discount rate, a lower assumed future P/E, and slightly softer margin expectations, partly offset by a higher projected revenue growth rate. What's in the News Sleep Cycle issued earnings guidance indicating an EBIT margin of about 5% for 2026, linked to increased forward-looking investments.Artículo de análisis • Feb 09
These Analysts Just Made An Downgrade To Their Sleep Cycle AB (publ) (STO:SLEEP) EPS Forecasts
One thing we could say about the analysts on Sleep Cycle AB (publ) ( STO:SLEEP ) - they aren't optimistic, having just...Artículo de análisis • Feb 07
Sleep Cycle (STO:SLEEP) Has Announced That Its Dividend Will Be Reduced To SEK0.53
Sleep Cycle AB (publ) ( STO:SLEEP ) is reducing its dividend from last year's comparable payment to SEK0.53 on the 20th...
Actualización del análisis • Feb 04
SLEEP: Data Partnerships Will Drive Future Upside For This Undervalued Play
Analysts have lifted their price target for Sleep Cycle from $26.00 to $34.50, citing updated assumptions that combine a lower discount rate and higher projected profit margin with a different revenue growth outlook and a higher future P/E multiple. What's in the News Sleep Cycle and the UK Health Security Agency began a 12 week research collaboration to test whether anonymised, privacy preserved data from the Sleep Cycle app and its Cough Radar tool can support respiratory disease surveillance and early detection of patterns for viruses such as influenza, RSV and Covid 19 (Key Developments).Actualización del análisis • Jan 21
SLEEP: Expanding Licensing And AI Coaching Will Drive Long Term Upside
Analysts have maintained their fair value estimate for Sleep Cycle at $43.00. They cite more cautious assumptions on revenue growth and profit margins, together with a higher future P/E outlook, as key factors behind the unchanged target.Actualización del análisis • Jan 06
SLEEP: Expanding Licensing And AI Sleep Coaching Will Support Long Term Upside
Analysts have kept their fair value estimate for Sleep Cycle steady at US$43.00, pointing to only small tweaks in the discount rate, expected revenue growth and profit margin, along with a slightly lower future P/E assumption as the basis for the unchanged target. What's in the News Sleep Cycle signed a multi year SDK licensing agreement with a global IoT and smart home device brand, allowing the customer to integrate the company’s audio based sleep tracking analysis into its devices and broadening Sleep Cycle’s technology licensing activity (Key Developments).Artículo de análisis • Jan 04
There's No Escaping Sleep Cycle AB (publ)'s (STO:SLEEP) Muted Earnings
Sleep Cycle AB (publ)'s ( STO:SLEEP ) price-to-earnings (or "P/E") ratio of 9.2x might make it look like a strong buy...Actualización del análisis • Dec 15
SLEEP: Long Term Profit Margins Will Drive Stronger Future Upside Potential
Analysts have trimmed their price target on Sleep Cycle from approximately $49.00 to $43.00. This reflects expectations for slower revenue growth, partially offset by higher long term profit margins and a lower future price to earnings multiple.Artículo de análisis • Sep 09
Sleep Cycle AB (publ) (STO:SLEEP) Held Back By Insufficient Growth Even After Shares Climb 30%
Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a really impressive month, gaining 30% after a shaky period...Artículo de análisis • Aug 27
Weekly Picks: 💸 A dividend-rich sleep-tech play few investors are watching, and 2 other picks.
The main catalyst behind Sleep Cycle’s upside potential, why JB Hi-Fi might have lost its point of difference, and the bear, base and bull case for Figma.
Actualización del análisis • Aug 23
Sleep Cycle's Revenue Set to Rise 10% with Strong Revenue Model
Q2 2025 Update (updated 250823) Subscriptions continue to decline (-3%), leading to a top-line contraction that is likely to persist. However, partnerships are gaining momentum , with the company highlighting on the conference call that these could carry a more favorable margin profile.Actualización del análisis • Aug 22
Expanding Technology And Sleep Apnea Initiatives Will Open New Opportunities
Sleep Cycle’s consensus price target has been revised upward, driven primarily by an increase in its future P/E multiple and a modest improvement in net profit margin, resulting in a new fair value estimate of SEK44.75. What's in the News Launched in-app promotion platform in collaboration with HelloFresh, Factor, and YouFoodz, enabling external brands to target Sleep Cycle’s user base with curated wellness offers and supporting expansion of partnership programs.Artículo de análisis • Apr 30
Earnings Update: Sleep Cycle AB (publ) (STO:SLEEP) Just Reported And Analysts Are Trimming Their Forecasts
As you might know, Sleep Cycle AB (publ) ( STO:SLEEP ) last week released its latest first-quarter, and things did not...Artículo de análisis • Apr 29
The Market Doesn't Like What It Sees From Sleep Cycle AB (publ)'s (STO:SLEEP) Earnings Yet As Shares Tumble 34%
Sleep Cycle AB (publ) ( STO:SLEEP ) shares have had a horrible month, losing 34% after a relatively good period...Artículo de análisis • Apr 08
Sleep Cycle's (STO:SLEEP) Dividend Will Be Increased To SEK3.00
Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...
Nuevo análisis • Mar 18
Medical-Grade Sleep Apnea Certification Will Open New Healthcare Partnerships
Exploring medical-grade certification and new revenue streams could enhance profitability, opening healthcare markets through partnerships and innovation.Artículo de análisis • Mar 06
Sleep Cycle's (STO:SLEEP) Upcoming Dividend Will Be Larger Than Last Year's
Sleep Cycle AB (publ) ( STO:SLEEP ) has announced that it will be increasing its dividend from last year's comparable...Artículo de análisis • Feb 10
Sleep Cycle (STO:SLEEP) Is Paying Out A Larger Dividend Than Last Year
Sleep Cycle AB (publ) ( STO:SLEEP ) will increase its dividend from last year's comparable payment on the 15th of April...Nuevo análisis • Feb 10
Sleep Cycle's Revenue Set to Rise 10% with Strong Business Model
Company will continue its trajectory of 10% top line growth p.a. with possibility of more aggressive growth should new business materialize (e.g. data monetization or making the app medical device forPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 298 | 47 | 46 | 67 | 2 |
| 12/31/2027 | 258 | 38 | 48 | 64 | 2 |
| 12/31/2026 | 218 | 10 | -29 | 16 | 2 |
| 3/31/2026 | 236 | 45 | 22 | 43 | N/A |
| 12/31/2025 | 248 | 53 | 40 | 53 | N/A |
| 9/30/2025 | 257 | 59 | 49 | 59 | N/A |
| 6/30/2025 | 261 | 62 | 56 | 66 | N/A |
| 3/31/2025 | 263 | 65 | 55 | 62 | N/A |
| 12/31/2024 | 262 | 63 | 60 | 64 | N/A |
| 9/30/2024 | 256 | 56 | 60 | 63 | N/A |
| 6/30/2024 | 251 | 55 | 64 | 66 | N/A |
| 3/31/2024 | 243 | 49 | 65 | 69 | N/A |
| 12/31/2023 | 236 | 46 | 46 | 53 | N/A |
| 9/30/2023 | 229 | 39 | 40 | 50 | N/A |
| 6/30/2023 | 224 | 33 | 31 | 41 | N/A |
| 3/31/2023 | 218 | 33 | 27 | 37 | N/A |
| 12/31/2022 | 212 | 34 | 54 | 62 | N/A |
| 9/30/2022 | 206 | 37 | 64 | 70 | N/A |
| 6/30/2022 | 199 | 34 | 64 | 71 | N/A |
| 3/31/2022 | 191 | 14 | 49 | 55 | N/A |
| 12/31/2021 | 183 | 8 | 14 | 20 | N/A |
| 9/30/2021 | 177 | 6 | 8 | 13 | N/A |
| 6/30/2021 | 168 | 12 | 17 | 19 | N/A |
| 3/31/2021 | 163 | 33 | 35 | 36 | N/A |
| 12/31/2020 | 159 | 44 | 46 | 46 | N/A |
| 12/31/2019 | 123 | 42 | N/A | 48 | N/A |
| 12/31/2018 | 93 | 27 | N/A | 53 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.3% al año) de SLEEP es superior a la tasa de ahorro (2%).
Beneficios vs. Mercado: Se prevé que los beneficios (13.3% al año) de SLEEP crezcan más rápidamente que el mercado Swedish (8.9% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de SLEEP crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (10% al año) de SLEEP crezcan más rápidamente que los del mercado Swedish (0.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 10% al año) de SLEEP crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de SLEEP sea alta dentro de 3 años (28.2%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/06 05:10 |
| Precio de las acciones al final del día | 2026/05/06 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Sleep Cycle AB (publ) está cubierta por 4 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Oscar Erixon | Carnegie Investment Bank AB |
| Erik Granström | DNB Carnegie |
| Rikard Engberg | DNB Carnegie Commissioned Research |